

## **Curis Regains Compliance with Nasdaq Continued Listing Requirements**

LEXINGTON, Mass., April 10, 2019 /[PRNewswire](#)/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") for continued listing on the Nasdaq Global Market. On December 27, 2018, the Company had received a letter from Nasdaq notifying it that it was not in compliance with the MVLS requirement set forth in Listing Rule 5450(b)(2)(A).

Dated April 9, 2019, the written confirmation from the Staff stated that as of April 8, 2019, the Company's MVLS has closed at \$50,000,000 or above for the last eleven consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(b)(2)(A) and will continue to trade on the Nasdaq Global Market.

### **About Curis, Inc.**

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene to develop first-in-class therapeutics in immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors, lymphomas, and mesothelioma and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

SOURCE Curis, Inc.

For further information: For further information: Investor Relations: Alex Fudukidis, Russo Partners, (646) 942-5632, [alex.fudukidis@russopartnersllc.com](mailto:alex.fudukidis@russopartnersllc.com); Media Relations: David Schull, Russo Partners, (212) 845-4271, [david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

---

<https://investors.curis.com/2019-04-10-Curis-Regains-Compliance-with-Nasdaq-Continued-Listing-Requirements>